(Quadrivalent Influenza mRNA Vaccine(Sanofi Pasteur)) - 在研适应症：流感病毒感染_专利_临床

概要

基本信息

药物类型

mRNA疫苗

别名

靶点-

作用机制

免疫刺激剂

治疗领域

感染呼吸系统疾病

在研适应症

流感病毒感染

非在研适应症-

原研机构

Sanofi Pasteur

在研机构

Sanofi Pasteur

非在研机构-

最高研发阶段临床1/2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

3

项与 Quadrivalent Influenza mRNA Vaccine(Sanofi Pasteur) 相关的临床试验

NCT06361875 / Recruiting临床1/2期

A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above

The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of different formulations of Quadrivalent Influenza Vaccine (QIV) messenger ribonucleic acid (mRNA) (MRT5421, MRT5424, and MRT5429) compared to an active control (QIV- standard dose (SD), QIV- high dose (HD) [adults ≥ 65 years of age only], or quadrivalent recombinant influenza vaccine (RIV4)) in adults 18 years of age and older.

开始日期2024-04-01

申办/合作机构

Sanofi Pasteur

NCT02554409 / CompletedN/A

Sanofi Pasteur Quadrivalent Intradermal Influenza Vaccine Pregnancy Registry Protocol

The Sanofi Pasteur Fluzone Intradermal Quadrivalent vaccine (Fluzone QIV-ID) Pregnancy Registry will be a prospectively recruited pregnancy surveillance program designed to collect to collect and analyze information on vaccine exposures, pregnancy outcomes, and fetal and offspring outcomes on pregnant women exposed to Fluzone QIV-ID vaccine.

开始日期2015-10-13

申办/合作机构

Sanofi Pasteur

NCT01945424 / CompletedN/A

Sanofi Pasteur Quadrivalent Influenza Vaccine Pregnancy Registry Protocol

The Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy Registry will be a prospectively recruited pregnancy surveillance program designed to collect and analyze information on vaccine exposures, pregnancy outcomes, and fetal and offspring outcomes.

开始日期2013-08-16

申办/合作机构

Sanofi Pasteur

100 项与 Quadrivalent Influenza mRNA Vaccine(Sanofi Pasteur) 相关的临床结果

登录后查看更多信息

100 项与 Quadrivalent Influenza mRNA Vaccine(Sanofi Pasteur) 相关的转化医学

登录后查看更多信息

100 项与 Quadrivalent Influenza mRNA Vaccine(Sanofi Pasteur) 相关的专利（医药）

登录后查看更多信息

100 项与 Quadrivalent Influenza mRNA Vaccine(Sanofi Pasteur) 相关的药物交易

登录后查看更多信息

研发状态

适应症	最高研发状态	国家/地区	公司
流感病毒感染	临床2期	美国更多	Sanofi Pasteur 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02451358 (CTgov)	临床3期	流感病毒感染	400	Quadrivalent Inactivated Influenza Vaccine (2016-2017 NH formulation), No Preservative (Quadrivalent Influenza Vaccine Group 1: 6 to 35 Months)	艱鹹簾廠餘齋製製夢膚(鹹鬱選鹹簾觸夢獵範製) = 願鬱積願觸觸醖艱夢願醖淵觸淵願網齋範夢窪 (鬱窪築構憲憲衊網齋構, 衊鑰廠網顧憲壓艱鹽網 ~ 衊壓遞積衊襯艱鑰簾廠) 更多	-	2018-03-01
				Quadrivalent Inactivated Influenza Vaccine (2016 SH formulation), No Preservative (Quadrivalent Influenza Vaccine Group 2: 3 to 8 Years)	艱鹹簾廠餘齋製製夢膚(鹹鬱選鹹簾觸夢獵範製) = 夢衊選齋鑰艱範製製醖醖淵觸淵願網齋範夢窪 (鬱窪築構憲憲衊網齋構, 觸餘壓醖觸觸蓋遞選蓋 ~ 鹹憲鬱糧鑰觸醖選網選) 更多
NCT04969276 (CTgov)	临床2期	接种疫苗 \| 流感病毒感染 \| 新型冠状病毒感染	306	Quadrivalent Inactivated Influenza High Dose (Group 2: Fluzone HD Quadrivalent Influenza Vaccine)	顧蓋網鏇鏇簾艱積窪構(醖簾願襯範淵鑰膚淵齋) = 鏇觸糧範壓鏇鬱製選願製糧衊衊餘範糧選願淵 (鬱襯構淵襯壓襯夢廠餘, 構鹽範選憲遞廠衊遞膚 ~ 艱壓齋顧廠觸選簾糧鬱) 更多	-	2022-12-13
				COVID-19 mRNA Vaccine (nucleoside modified) (Group 3: COVID-19 Vaccine)	顧蓋網鏇鏇簾艱積窪構(醖簾願襯範淵鑰膚淵齋) = 製積衊蓋襯鑰獵鏇艱構製糧衊衊餘範糧選願淵 (鬱襯構淵襯壓襯夢廠餘, 鹹願窪夢範範壓鏇鑰觸 ~ 廠窪鏇膚夢網遞選繭衊) 更多